In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Perlegen and Mitsubishi in cross-licensing metabolic deal

Executive Summary

In a cross-licensing agreement, Perlegen Sciences (pharmacogenetics; Affymetrix spin-off) has gained exclusive worldwide development and commercialization rights, excluding Asia, to Mitsubishi Pharma's MCC-555 (netoglitazone) to treat diabetes and other metabolic disorders. In turn, Mitsubishi gets exclusive rights in Asia to Perlegen's predictive genetic markers for use with MCC-555.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Alliance
    • Product or Technology Swap
    • R&D and Marketing (Licensing)

Related Companies